Overall mortality in combined pulmonary fibrosis and emphysema related to systemic sclerosis

• Autor(a) principal: Ariani, Alarico
• Data de Publicação: 2019
• Outros Autores: Silva, Mário, Bravi, Elena, Parisi, Simone, Saracco, Marta, De Gennaro, Fabio, Caimmi, Cristian, Girelli, Francesco, De Santis, Maria, Volpe, Alessandro, Lumetti , Federica, Hax, Vanessa, Bredemeier, Markus, Alfieri, Veronica, Santilli, Daniele, Bodini, Flavio Cesare, Lucchini, Gianluca, Mozzani, Flavio, Seletti, Valeria, Bacchini, Emanuele, Arrigoni, Eugenio, Giuggioli, Dilia, Chakr, Rafael Mendonça da Silva, Idolazzi, Luca, Bertorelli, Giuseppina, Imberti, Davide, Michieletti, Emanuele, Paolazzi, Giuseppe, Fusaro, Enrico, Chetta, Alfredo Antonio, Scirè, Carlo Alberto, Sverzellat, Nicola
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFRGS
• Texto Completo: http://hdl.handle.net/10183/200843
• topic: Fibrose pulmonar idiopática; Enfisema pulmonar; Escleroderma sistêmico; Mortalidade; Estimativa de Kaplan-Meier; Declaração de Helsinki

OBJECTIVES: This multicentre study aimed to investigate the overall mortality of combined pulmonary fibrosis and emphysema (CPFE) in systemic sclerosis (SSc) and to compare CPFE-SSc characteristics with those of other SSc subtypes (with interstitial lung disease-ILD, emphysema or neither). METHODS: Chest CTs, anamnestic data, immunological profile and pulmonary function tests of patients with SSc were retrospectively collected. Each chest CT underwent a semiquantitative assessment blindly performed by three radiologists. Patients were clustered in four groups: SSc-CPFE, SSc-ILD, SSc-emphysema and other-SSc (without ILD nor emphysema). The overall mortality of these groups was calculated by Kaplan-Meier method and compared with the stratified log-rank test; Kruskal-Wallis test, t-Student test and χ² test assessed the differences between groups. P<0.05 was considered statistically significant. RESULTS: We enrolled 470 patients (1959 patient-year); 15.5 % (73/470) died during the follow-up. Compared with the SSc-ILD and other-SSc, in SSc-CPFE there was a higher prevalence of males, lower anticentromere antibodies prevalence and a more reduced pulmonary function (p<0.05). The Kaplan-Meier survival analysis demonstrates a significantly worse survival in patients with SSc-CPFE (HR vs SSc-ILD, vs SSc-emphysema and vs other-SSc, respectively 1.6 (CI 0.5 to 5.2), 1.6 (CI 0.7 to 3.8) and 2.8 (CI 1.2 to 6.6). CONCLUSIONS: CPFE increases the mortality risk in SSc along with a highly impaired lung function. These findings strengthen the importance to take into account emphysema in patients with SSc with ILD.